- VERAXA Biotech is changing how antibody-based therapies recognize and attack cancer cells, developing antibody-based cancer therapies with an emphasis on bispecific antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”).
- Its proprietary BiTAC platform uses a dual-targeting, “AND-gated” architecture designed to activate therapeutic effects preferentially at tumor sites.
- The company has advanced its lead BiTAC-TCE toward IND/CTA-enabling activities following cell-line development work and regulatory feedback from Germany’s Paul-Ehrlich-Institute.
- VERAXA’s VXA-222 bispecific ADC has moved beyond the initial discovery phase following completion of the antibody-discovery step with OmniAb.
- The company reported more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, alongside additional pending applications.
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is advancing its oncology pipeline with a strategy centered on changing how antibody-based therapies recognize and attack cancer cells. The biotechnology company is developing bispecific antibody-drug conjugates, T-cell engagers and other engineered antibody formats, with its proprietary BiTAC technology providing the distinctive element of its approach.
The latest pipeline development involves VXA-222, a bispecific antibody-drug conjugate that has moved beyond the initial discovery phase following the completion of VERAXA’s collaboration with OmniAb. VERAXA is now responsible for engineering the final therapeutic candidate using antibody binders generated through the collaboration, followed by…
NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://nnw.fm/VRXA
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN
